Longitudinal dialysis adequacy and clinical performance of the VectorFlow hemodialysis catheter: a prospective study
| Autor: | Tatiana Puga, John Ross, Thomas Philbeck |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Catheter Obstruction
Male medicine.medical_specialty Catheterization Central Venous Time Factors medicine.medical_treatment 030232 urology & nephrology Hemodialysis Catheter Lumen (anatomy) 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Catheters Indwelling Renal Dialysis Risk Factors Medicine Central Venous Catheters Humans Prospective Studies Prospective cohort study Aged Dialysis adequacy business.industry Clinical performance Equipment Design Middle Aged Texas Surgery Equipment failure Catheter Treatment Outcome Nephrology Regional Blood Flow Catheter-Related Infections Kidney Failure Chronic Equipment Failure Female Hemodialysis business Blood Flow Velocity |
| Zdroj: | The journal of vascular access. 18(6) |
| ISSN: | 1724-6032 |
| Popis: | Purpose To report clinical performance and longitudinal assessment of hemodialysis adequacy with the Arrow-Clark VectorFlow catheter, a symmetrical-tip device with a distal lumen configuration designed to reduce platelet shear stress and catheter thrombosis. Methods and materials We prospectively enrolled patients who required de novo placement of a chronic tunneled catheter for hemodialysis or exchange of a dysfunctional catheter as part of an Institutional Review Board (IRB)-approved protocol. Catheter patency, Kt/V, mean blood-flow (Qb), and pump pressures were obtained at baseline and at monthly intervals to 90 days. Results Forty-six subjects were enrolled into the study. During the 90-day observation period, maximum blood-flow rate averaged 355-398 mL/minute; mean Qb averaged 333-392 mL/minute. Mean Kt/V values were consistently ≥1.5. Dwell-time was 15-114 days, for a total of 2997 catheter days (mean 71.4 days). Excluding patients who died during the study and those receiving surgical access, overall intervention-free catheter patency rate was 94.9%, 92.2% and 88.8% at days 30, 60, 90, respectively. There were no acute complications. During the follow-up period, three patients developed complications (6.5%). Two catheter infections occurred (0.7/1000 catheter days) and one catheter malfunctioned; a rate of 1.0/ 1000 catheter days for all complications. Conclusions The VectorFlow catheter produced safe, effective hemodialysis with Kt/V ≥1.5. A single catheter occlusion occurred and a low rate of infection was seen. Results support the hypothesis that the VectorFlow design reduces thrombogenic risk during clinical performance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|